Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022


Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Summary

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Menveo (Meningococcal groups A, C, Y, W-135 oligosaccharide diphtheria CRM197 conjugate vaccine) is Novartis' tetravalent conjugate vaccine licensed in the US, EU, Australia, and Brazil to protect against four serogroups of N. meningitidis (A, C, Y, W-135) that cause meningococcal disease in children, adolescents, and adults. Approved in 2010 for all markets in this report, Menveo was the second tetravalent conjugate vaccine to enter the market in US and Australia and the first to enter the 5EU markets.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Menveo including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Menveo for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Menveo performance
- Obtain sales forecast for Menveo from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 16
3.3 Prognosis 17
4 Disease Management 18
4.1 Meningococcal Immunization Policy 19
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 22

6 Menveo 24
6.1 Overview 24
6.2 Efficacy 26
6.3 Safety 26
6.4 SWOT Analysis 27
6.5 Forecast 27
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 31
7.3 Methodology 32
7.4 Forecasting Methodology 32
7.4.1 Vaccine Coverage 33
7.4.2 Vaccine Approval vs. Routine Schedule Inclusion 34
7.4.3 Vaccines Included 34
7.4.4 Key Launch Dates 34
7.4.5 General Pricing Assumptions 35
7.4.6 Individual Vaccine Assumptions 36
7.5 Physicians and Specialists Included in this Study 37
7.6 About the Authors 41
7.6.1 Authors 41
7.6.2 Reviewers 41

7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

List of Tables

Table 1: Symptoms of Meningococcal Disease 16
Table 2: Meningococcal Immunization Recommendation Agencies by Country 20
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 21
Table 4: Leading Vaccines for Meningococcal Disease, 2012 23
Table 5: Product Profile – Menveo 25
Table 6: Menveo SWOT Analysis, 2012 27
Table 7: Global Sales Forecasts ($m) for Menveo, 2012–2022 28
Table 8: Key Launch Dates 35
Table 9: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 40

List of Figures

Figure 1: Membrane Structure of N. meningitidis 13

Read the full report:
Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022
http://www.reportbuyer.com/pharma_healthcare/therapeutic/menveo_meningococcal_vaccines_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com   
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer